New wrinkle treatment shows promise in small study
NCT ID NCT05148000
First seen May 31, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This study tested a new botulinum toxin product called QM1114-DP in 25 adults with moderate to severe frown lines and crow's feet. Participants received one treatment and were asked to rate the change in their appearance. Most reported at least some improvement. The study is complete, but larger trials are needed to confirm these results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLABELLAR FROWN LINES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Galderma Research Site
New York, New York, 10021, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QM1114-DP (a botulinum toxin type A product)
What this could lead to
If it works, this could offer a new option for temporarily reducing frown lines and crow's feet.
What could go wrong
This is a small, completed Phase 3 study with only 25 participants. Results may not apply to everyone, and risks include allergic reactions or temporary muscle weakness.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.